Melanoma: From incurable beast to a curable bet. The success of immunotherapy

Maria Libera Ascierto, Ignacio Melero, Paolo A. Ascierto

Research output: Contribution to journalArticlepeer-review


After Coley's observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types which translates into improved overall survival benefit. Here, we provide an overview of the main immuneoncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.

Original languageEnglish
Article number152
JournalFrontiers in Oncology
Issue numberJUN
Publication statusPublished - 2015


  • Adoptive T cell therapy
  • Combination therapy
  • Immunomodulatory antibodies
  • Immunotherapy
  • Melanoma
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Melanoma: From incurable beast to a curable bet. The success of immunotherapy'. Together they form a unique fingerprint.

Cite this